Print Page  Close Window

Investor Relations

Corporate Profile
Eyenovia is a late-stage biopharmaceutical company with three lead programs in glaucoma, mydriasis and dry eye with a transformative ophthalmic delivery platform. Using breakthrough piezo-print technology for high-precision micro-dosing and the first smart electronic mobile health compliance tracking platform for topical pharmaceuticals, Eyenovia is building a premier eye care company of the future. The company is advancing its two lead assets for glaucoma and mydriasis into Phase III clinical programs and preparing registration studies for a third OTC product for dry eye. Eyenovia is expected to complete all three development programs through registration by 2020. Eyenovia is building a portfolio of superior micro-therapeutics with its proprietary piezo-formulations of existing and new molecular entities.

Price
$8.25

Change
 - 0.24 (2.83%)

Volume
11,249

Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News Releases
06/11/18
Eyenovia to Present at the JMP Securities 2018 Life Sciences Conference
Read More
06/05/18
Eyenovia Receives Notices of Allowance from USPTO on Two Additional Patent Applications for Ophthalmic Drug Delivery
Read More
05/09/18
Eyenovia Reports First Quarter 2018 Financial Results and Completion of EYN PG21 Study
Read More
Upcoming Events
DateTitle
06/20/18 1:30 p.m. ET
Eyenovia Presentation at the JMP Securities Life Science Conference

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY  11219
(718) 921-8124 (phone)
(718) 921-8386 (fax)
[email protected]